Perioperative Management of Factor Xa Inhibitors

• Status: Recruiting
• Trial end date: 2025-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to analyze the safety and effectiveness of the discontinuation/resumption protocol of factor Xa inhibitors before and after invasive procedures/surgeries in non-valvular atrial fibrillation patients who are at risk of minor bleeding in actual clinical settings

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Factor Xa Inhibitors

Criteria

Inclusion Criteria:

• Aged >20 years

• With rivaroxaban, apixaban, or edoxaban

• History of non-valvular atrial fibrillation

• Scheduled minor bleeding risk procedure(s) (dental procedure, cataract/glaucoma surgery, diagnostic GI endoscopy)

Exclusion Criteria:

• Pregnancy

• With rivaroxaban or edoxaban at afternoon

• Mental disorder

• Contraindication to rivaroxaban, apixaban, edoxaban

• Moderate or severe valvular heart disease, or with prosthetic heart valves

• With antiplatelet drugs

• History of systemic embolism or ischemic stroke within the last 12 months

• scheduled therapeutic endoscopic procedure(s)